Dianthus Therapeutics launches $150 mln equity offering after shares surge

Dianthus Therapeutics

08/09/2025 21:18

**  Dianthus Therapeutics' DNTH.O shares dip 3% in extended trading as co looks to capitalize on its surging share price by raising equity

    ** DNTH shares ended regular session on Mon up 20% at $31.80 after co said its muscle-weakening drug claseprubart improved symptoms in adults with generalized myasthenia gravis in a mid-stage trial

    ** After the bell, co commences $150 mln stock offering to fund preclinical and clinical development activities, and for working capital and general purposes

    ** Jefferies, TD Cowen, Evercore and Stifel are joint bookrunners

    ** Dianthus has ~32.19 mln shares outstanding for about $1 bln market cap

    ** Shares up ~46% YTD through Mon close

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))